Chemotherapy-Induced Neutropenia Market

Market Overview:

The 7 major chemotherapy-induced neutropenia markets reached a value of US$ 371.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 455.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.88% during 2024-2034.

The chemotherapy-induced neutropenia market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced neutropenia refers to a serious consequence of cancer chemotherapies, in which the number of neutrophils in the blood drops below a healthy level. This loss of neutrophils results in the disruption of immune defense mechanisms and enhances the likelihood of infections. The common symptoms associated with this ailment include fever, chills, sores in the mouth, cough, difficulty breathing, abdominal or rectal pain, etc. In some cases, patients suffering from the disease may also experience diarrhea, swollen lymph nodes, and urinary symptoms, like burning urination with urgency and frequency. Diagnosing this ailment is typically based on a review of underlying symptoms, patient’s medical history, and laboratory studies. The healthcare professionals may also perform a complete blood count to determine the absolute neutrophil count of the patient. In some cases, additional testing may be utilized to evaluate the underlying cause of chemotherapy-induced neutropenia. This may include a biopsy, in which a sample of the bone marrow is examined under a microscope to identify abnormalities associated with the indications and confirm a diagnosis.

The escalating utilization of chemotherapeutic drugs for cancer treatment, which can cause damage to healthy neutrophils and the bone marrow that produces white blood cells, is primarily driving the chemotherapy-induced neutropenia market. Moreover, the widespread adoption of effective drugs, such as granulocyte colony-stimulating factors to boost neutrophil production and help protect against infection, is also bolstering the market growth. In addition to this, the inflating application of disease diagnostic tools, such as a bone marrow aspiration test to measure if the bone marrow is healthy and producing normal amounts of blood cells, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to launch cost-effective injectable treatment alternatives due to quicker onset of action and faster symptom relief. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of pegfilgrastim solutions for treating the ailment, since it can significantly increase peripheral blood neutrophil counts and has low renal clearance, is further expected to drive the chemotherapy-induced neutropenia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced neutropenia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chemotherapy-induced neutropenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced neutropenia market in any manner.

Recent Developments:

• In November 2023, Evive Biotech, a subsidiary of Yifan Pharmaceuticals Co. Ltd., and Acrotech Biopharma declared that on November 16, 2023, the U.S. Food and Drug Administration (FDA) approved Ryzneuta (Efbemalenograstim alfa) to reduce febrile neutropenia in adult patients with non-myeloid malignancies taking myelosuppressive anticancer drugs.

Key Highlights:

• Half of cancer patients getting chemotherapy have some amount of neutropenia.
• In the United States, the incidence of chemotherapy-induced neutropenia is 2.4-15.4 cases/million each year.
• Patients who are over the age of 65 have a higher risk of developing chemotherapy-induced neutropenia.
• Chemotherapy-induced neutropenia was noted to be associated with platinum-based regimens, taxane-containing regimens, and the number of anticancer drugs in regimens.
• Cancer patients with diabetes mellitus or hyperglycemia are 32% more likely to develop chemotherapy-induced neutropenia than patients without these two
  diseases.

Drugs:

ROLVEDON (eflapegrastim-xnst) injection is a new formulation of the long-acting granulocyte colony-stimulating factor (G-CSF). Spectrum has been approved to reduce the incidence of infection, as shown by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anticancer medicines that are linked with a clinically significant incidence of febrile neutropenia.

Plinabulin is a selective immunomodulating microtubule-binding drug that stimulates antigen-presenting cells (APCs). It is a new, intravenous-infused, patent-protected, NDA-stage product for preventing chemotherapy-induced neutropenia.

myelo001 is an under-investigational drug by Myelo Therapeutics GmbH. This therapeutic candidate is a small molecule that could provide a cheaper and safer alternative to the standard-of-care G-CSF to prevent and treat chemotherapy-induced neutropenia.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chemotherapy-induced neutropenia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chemotherapy-induced neutropenia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chemotherapy-induced neutropenia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chemotherapy-induced neutropenia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chemotherapy-induced neutropenia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chemotherapy-induced neutropenia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of chemotherapy-induced neutropenia across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of chemotherapy-induced neutropenia by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of chemotherapy-induced neutropenia by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with chemotherapy-induced neutropenia across the seven major markets?
• What is the size of the chemotherapy-induced neutropenia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (​2024-2034​) across the seven major markets?
• What are the key factors driving the epidemiological trend of chemotherapy-induced neutropenia?
• What will be the growth rate of patients across the seven major markets?
   

Chemotherapy-Induced Neutropenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chemotherapy-induced neutropenia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced neutropenia market?
• What are the key regulatory events related to the chemotherapy-induced neutropenia market?
• What is the structure of clinical trial landscape by status related to the chemotherapy-induced neutropenia market?
• What is the structure of clinical trial landscape by phase related to the chemotherapy-induced neutropenia market?
• What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced neutropenia market?